Synopsis: A leading brokerage has turned bullish on a diversified pharma player, initiating coverage with a rating that points to a sizeable upside from current levels, citing strength across chronic therapies at home and a scaling international business.
Brokerage initiations often signal where analysts expect the next leg of growth to come from in a sector, and the pharmaceutical space has seen fresh interest this week. A domestic brokerage has flagged a company built on a mix of steady chronic therapy leadership in India and an expanding footprint across international markets, calling out multiple growth drivers rather than dependence on a single segment or geography.
Motilal Oswal Turns Bullish
Motilal Oswal Financial Services has initiated coverage on Emcure Pharmaceuticals with a “Buy” rating and a target price of Rs 2,260, implying an upside of more than 20% from current levels. The brokerage’s thesis rests on what it calls a “multi-engine growth story” – a business that isn’t leaning on any single market or therapy area to drive numbers, but instead pulling growth from several directions at once: a well-entrenched domestic franchise, a scaling international business, and a pipeline of complex, harder-to-replicate products.
According to the brokerage, Emcure has built a diversified, chronic-focused domestic portfolio anchored around its leadership in women’s health, while steadily expanding into cardiology, CNS, anti-diabetes, HIV and oncology. This spread across therapies is seen as a key differentiator, reducing dependence on any one segment and giving the company multiple levers to pull for future growth.
Growth Estimates Point to Strong Compounding
Motilal Oswal has pencilled in a healthy trajectory for the company between FY26 and FY28, projecting revenue to grow at around 14% annually on a compounded basis, with EBITDA expected to expand faster at roughly 20% CAGR, and profit after tax climbing at an even sharper 28% CAGR. The brokerage attributes this to a combination of a differentiated product mix and an efficient commercial network that helps the company get products to market faster and more profitably.
A Look at the Numbers
The company’s own recent disclosures support the growth narrative the brokerage is building on. On a consolidated basis, revenue from operations for FY26 came in at Rs 9,204 crore, up 16.6% over the previous year, a growth rate the company said was ahead of its own guidance and led largely by strong performance in international markets.
EBITDA for the year stood at Rs 1,789 crore, translating into a margin of 19.4%, an improvement of 80 basis points over the previous year. Adjusted profit after tax rose to Rs 1,008 crore, with margins improving nearly 190 basis points to 10.9%. Return on capital employed, a gauge of how efficiently the company is using its capital, also moved up to 23.8% for the year.
Domestically, revenue touched Rs 4,027 crore, growing broadly in line with the overall Indian pharmaceutical market, led by cardiac, CNS and oncology segments. The company has also been strengthening its India portfolio through partnerships, including a recent tie-up to market a biological injectable version of semaglutide, a drug widely used for weight management.
Global Business Gaining Scale
The international business has emerged as a bigger growth driver, with revenue rising over 22% for the year. Growth was fairly broad-based across geographies – Europe, Canada and other emerging markets all posted double-digit gains, helped by new product launches and market share gains in complex injectables and generics.
The company has also been building out its pipeline in areas like biologics, novel drug delivery systems and long-acting injectables, positioning itself for growth beyond the near term.
The Bigger Picture
What seems to be drawing brokerage attention is less about any single quarter’s numbers and more about the underlying structure of the business – a company that has scaled across markets without over-relying on one geography or therapy, paired with margin expansion driven by better productivity and capacity utilisation rather than one-off factors.
Whether the stock delivers on the kind of upside Motilal Oswal is projecting will depend on execution across these many moving parts, but the brokerage’s initiation adds a fresh data point to a stock that investors have increasingly started watching more closely.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
